T1	intervention 23 38	lipegfilgrastim
T2	control 46 59	pegfilgrastim
T3	eligibility 607 717	Patients with high-risk stage II, III, or IV breast cancer and an absolute neutrophil count ≥1.5 × 109 cells/L
T6	iv-cont-mean 1080 1083	0.7
T7	cv-cont-mean 1088 1096	0.8 days
T9	iv-bin-percent 1221 1224	56%
T10	cv-bin-percent 1229 1232	49%
T8	outcome 1183 1204	no severe neutropenia
T11	outcome 1348 1367	febrile neutropenia
T12	cv-bin-abs 1380 1385	three
T13	iv-bin-abs 1438 1442	zero
T14	outcome 1477 1504	Drug-related adverse events
T15	iv-bin-percent 1547 1550	28%
T16	cv-bin-percent 1555 1558	26%
T4	outcome-Measure 931 976	duration of severe neutropenia during cycle 1
T5	outcome 991 1026	mean duration of severe neutropenia
T17	intervention-participants 798 801	101
T18	control-participants 825 828	101
